ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome: AQ, EQ and SQ

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00505830
Recruitment Status : Unknown
Verified July 2007 by Groupe Francais d'Epidemiologie Psychiatrique.
Recruitment status was:  Recruiting
First Posted : July 25, 2007
Last Update Posted : July 25, 2007
Sponsor:
Collaborator:
Joint Clinical Research Center
Information provided by:
Groupe Francais d'Epidemiologie Psychiatrique

Study Description
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Autism is considered as an invading disorder of the development. Asperger Syndrome (AS) is a particular form of autism and is difficult to diagnose. The Autism Spectrum Quotient (AQ) has been developed in order to measure the degree of autistic traits in autistic adolescent with normal intelligence (Baron-Cohen et al. 2001, 2006). AQ comprises 50 questions, with 5 groups of 10 questions assessing imagination, social skills, attention switching, attention to detail and communication skills. Each of these items scores 1 point if the respondent records abnormal or autistic like behaviour. The minimum score on the AQ is 0 and the maximum 50.

The principal objective of this study is to evaluate the accuracy of the French version of Autism Spectrum Quotient questionnaire.

Secondary objectives are to:

Evaluate if EQ and SQ can distinguish adolescents without psychiatric syndromes from those with classical autism or AS.

Evaluate if AQ, EQ and SQ can distinguish adolescents with psychiatric disorders from autistic adolescents.

Define the threshold of positivity for the 3 questionnaires.


Condition or disease Intervention/treatment
Asperger Syndrome Autism Other: questionnaires

Detailed Description:

4 groups of participants will be screened with the questionnaires: Group 1: 50 adolescents with AS or high functioning autism (HFS) diagnosed by psychiatrists using established criteria and with an IQ >85.

Group 2: 50 adolescents with AS or classical autism diagnosed by psychiatrists using established criteria 70<IQ<84.

Group 3: 50 adolescents with psychiatric disorders. Group 4: Sample of 50 healthy adolescents selected randomly from 200. The questionnaires are given to the parents of adolescents during the first meeting. Parents are invited to send them back to the clinical investigation centre of Lyon (France).

Multicentre study: 8 clinical centres and 18 paediatricians


Study Design
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Observational
Estimated Enrollment : 450 participants
Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome : Autism Spectrum Quotient (AQ) Empathy Quotient (EQ) and Systemizing Quotient (SQ)
Study Start Date : July 2007
Estimated Study Completion Date : July 2009
Groups and Cohorts
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Case: 1
50 adolescents with AS or high functioning autism (HFS) diagnosed by psychiatrists using established criteria and with an IQ >85.
 Other: questionnaires

Primary outcome:

Autism Spectrum Quotient (AQ)

Secondary outcome measure:

Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score
Case: 2
50 adolescents with AS or classical autism diagnosed by psychiatrists using established criteria 70<IQ<84.
 Other: questionnaires

Primary outcome:

Autism Spectrum Quotient (AQ)

Secondary outcome measure:

Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score
Control: 3
50 adolescents with psychiatric disorders but no autism syndrom.
 Other: questionnaires

Primary outcome:

Autism Spectrum Quotient (AQ)

Secondary outcome measure:

Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score
Control: 4
Sample of 50 healthy adolescents selected randomly from 200.
 Other: questionnaires

Primary outcome:

Autism Spectrum Quotient (AQ)

Secondary outcome measure:

Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score


Outcome Measures
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Eligibility Criteria
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Group 1 (AS/HFA) and 2 (AS/classic autism) :

  • Boys and girls aged 12 to 18
  • Patients with autism or Asperger syndrome according to the diagnostic criteria (ICD 10)
  • Patients receiving education in an ordinary school
  • IQ>70

Group 3 (adolescents with psychiatric disorders):

  • Boys and girls aged 12 to 18
  • Patients hospitalized on a psychiatric ward or at a psychiatrics patient visit or psychiatric consultation wit hout autistic syndrome
  • Patients receiving education in an ordinary school when not in hospital

Group 4 (adolescent without psychiatric syndrome):

  • Boys and girls aged 12 to 18
  • Patients receiving education in an ordinary school

Exclusion Criteria:

For all groups :

  • Problem with language or comprehension
  • Participants who have not given their consent
Contacts and Locations
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00505830


Contacts
Contact: Jean-Pierre Vignat, MDH +33 4 37 90 11 75 jpvignat@ch-st-jean-de-dieu-lyon.fr

Locations
France
Centre Hospitalier Saint Jean de Dieu Recruiting
Lyon, France
Contact: Sabine Manificat, MDH    +33 4 37 90 12 96    smanificat@arhm-sjd.fr   
Contact: Berhouz Kassai, MD, PhD       bk@upcl.univ-lyon1.fr   
Sponsors and Collaborators
Groupe Francais d'Epidemiologie Psychiatrique
Joint Clinical Research Center
Investigators
Principal Investigator: Sabine Manificat, MDH Centre Hospitalier Saint Jean de Dieu
More Information
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

ClinicalTrials.gov Identifier: NCT00505830     History of Changes
Other Study ID Numbers: Autisme AQ
First Posted: July 25, 2007    Key Record Dates
Last Update Posted: July 25, 2007
Last Verified: July 2007

Keywords provided by Groupe Francais d'Epidemiologie Psychiatrique:
Asperger Syndrom
Autism Quotient
French version
 screening
diagnostic test
accuracy

Additional relevant MeSH terms:
Syndrome
Autistic Disorder
Asperger Syndrome
Disease
 Pathologic Processes
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Mental Disorders